Regeneron Pharmaceuticals
REGN
908 hedge funds and large institutions have $51.6B invested in Regeneron Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 102 funds opening new positions, 371 increasing their positions, 314 reducing their positions, and 119 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 371 | Existing positions reduced: 314
4.27% more ownership
Funds ownership: 83.95% → 88.22% (+4.3%)
2% less call options, than puts
Call options by funds: $901M | Put options by funds: $921M
3% less funds holding
Funds holding: 933 → 908 (-25)
11% less capital invested
Capital invested by funds: $57.9B → $51.6B (-$6.28B)
14% less first-time investments, than exits
New positions opened: 102 | Existing positions closed: 119
32% less funds holding in top 10
Funds holding in top 10: 25 → 17 (-8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$155M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$143M |
| 3 |
Renaissance Technologies
New York
|
+$111M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$86.8M |
| 5 |
HM
HealthCor Management
New York
|
+$81.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Harris Associates
Chicago,
Illinois
|
-$340M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$176M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$169M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$127M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$112M |
REGN Hedge Fund Activity: Q3 2020 in Review
908 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q3 2020, worth a combined $51.6B — down 11% from $57.9B a quarter earlier.
Sellers outnumbered buyers: 119 funds closed out of REGN and 102 opened new positions — a net loss of 17 holders — while 314 trimmed existing stakes and 371 added.
The largest buyer was Fidelity Investments, adding an estimated $155M. The largest seller was Harris Associates, cutting an estimated $340M.
- 908 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q3 2020, down from 933 in Q2 2020.
- Funds reported $51.6B of Regeneron Pharmaceuticals stock for Q3 2020, down 11% quarter-over-quarter.
- 102 funds opened new Regeneron Pharmaceuticals positions in Q3 2020 and 119 closed out, a net change of -17 holders.
- The largest Regeneron Pharmaceuticals buyer in Q3 2020 was Fidelity Investments, an estimated $155M added.
- The largest Regeneron Pharmaceuticals seller in Q3 2020 was Harris Associates, an estimated $340M sold.
Based on aggregated 13F filings for Q3 2020.